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ABSTRAK
Neurotoksin  Clostridium botulinum (BoNTs) merupakan salah satu  penyebab kerugian ekonomi 
bagi industri peternakan. Kerugian ini dapat sebagai akibat langsung ketika ternak keracunan BoNTs 
atau secara tidak langsung ketika produk asal ternak terkontaminasi BoNTs sehingga produk tersebut 
dilarang  untuk  dipasarkan.  Untuk  itu  perlu  dilakukan  pengontrolan  rutin  penyebaran  BoNTs  di 
lingkungan peternakan dan industri hasil ternak. Salah satu caranya adalah dengan melakukan deteksi 
rutin terhadap keberadaan BoNTs. Salah satu metode deteksi yang relatif cepat dan akurat adalah metode 
enzyme linkage immunosorbant  assay (ELISA).  Pada penelitian ini  dilaporkan hasil  pengembangan 
ELISA, menggunakan antibodi  poliklonal produk lokal terhadap BoNTs-B.  Antibodi dihasilkan dari 
enam mencit  Balb/c  dengan metode imunologi standar.  Mencit  diimunisasi 3 kali  selama 8 minggu 
dengan toksoid C. Botulinum tipe B komersial dengan dosis 100 ng per ekor per injeksi. Antibodi yang 
dihasilkan dimurnikan dengan kombinasi metode presipitasi ammonium sulfat  50% (w/v) dan kolom 
protein A. Hasil studi pendahuluan ini menunjukkan bahwa metode ELISA yang dikembangkan mampu 
mendeteksi toksin Clostridium botulinum tipe B hingga 1,0 ng/ml.
Kata kunci: toksin C. botulinum, ELISA, antibodi poliklonal
ABSTRACT
Clostridium botulinum neurotoxin (BoNTs) is one of the causes of economic loss in the livestock 
industry. This economic loss would be as a direct result when animals poisoned by BoNTs or indirectly 
when the livestock products are contaminated by BoNTs, which end up with the products are banned by 
authority. Therefore a routine surveillance of BoNTs in the farm and in livestock product processing 
industry is urgently needed. One of the most relatively quick and accurate methods to perform a routine 
detection of the presence of BoNTs is enzyme-linkage immunosorbant assay (ELISA). In this article we 
describe  the  results  of  the  development  of  ELISA,  using  polyclonal  antibodies  against  BoNTs-B 
produced  locally.  Antibodies  were  generated  from  six  Balb/c  mice  with  standard  immunological 
methods.  Mice  were  immunized  three  times  for  a  period  of  8  weeks  with  a  commercial  type  B 
Clostridium botulinum toxoid at a dose of 100 ng per mouse per injection. The resulting antibody was 
purified by a  combination of  ammonium sulfate precipitation 50% (w/v)  technique and a  protein  A 
column method.  The results  of  this  preliminary study indicated  that  the developed ELISA method 
capable of detecting type B Clostridium botulinum toxin up to 1.0 ng/ml.
Keywords: C. botulinum toxin, ELISA, polyclonal antibody.
INTRODUCTION
Clostridium  botulinum neurotoxin  (BoNTs) 
is the causative agent of botulism, a fatal disease 
characterized by muscular paralysis, which affect 
mammals,  birds,  and fish (Keto-Timonen  et al., 
2005, Steinman et al., 2006). Livestock botulism 
is  a  worldwide  problem  that  causes  large 
economic  losses  (Steinman  et  al.,  2006). The 
losses that incurred on the farm industry can be 
happened  directly  or  indirectly.  The direct  loss 
occurred  when  the  animal  is  attacked  directly, 
such  as  when  they  ingest  C.  botulinum spores 
contaminated  feed.  Indirect  losses  arose  if  the 
spores  are  found  in  animal  processed  products 
such as sausages or burgers (Shapiro et al., 1998), 
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even in honey (Nevas et al., 2002), which in turn 
causes  the products  are no  longer  economically 
valuable  even  banned  by  the  authority.  To 
overcome  the  problems  early  prevention  is 
needed. This can be done by both routine handling 
of the livestock sanitary as well as maintaining the 
hygiene  of  processing  livestock  products.  In 
addition routine screening tests again BoNTs are 
required. 
Commonly test method performed is mouse 
bioassay,  which measures the resistance of  mice 
to the toxin (Witcome et al., 1999; Gessler  et al., 
2005). The assay is able to detect up to one unit 
dose of one mouse lethal dose (1 MLD), which is 
equivalent  to  approximately  10  pg/ml  of 
neurotoxins  (Sharma  et  al.,  2005).  Hence,  this 
method is  categorized  quite  sensitive.  However, 
the operational cost  of  this  method is relatively 
high  due  to  the  need  of  mice  with  specific 
conditions.  Furthermore  it  takes  special  skills, 
animal ethics concerns, as well as the specificity 
of neurotoxins detected is still very limited. It also 
needs  quite  long  time  to  get  results,  which  is 
about  4  days  or  more  (Sharma  et  al.,  2005). 
Consequently  several  methods  have  been 
developed ranging from ELISA (Dezfulian et al., 
1984;  Witcome  et  al.,  1999),  immunoaffinity 
chromatographic  column  test  (Gessler  et  al., 
2005), fluorogenic assay (Anne et al., 2001), up to 
the bio-molecular test  such as PCR (Fach  et al., 
1995;  Braconnier  et  al.,  2001;  Kimura  et  al., 
2001; Lindstrom et al., 2001; Fach et al., 2002). 
The advantages of the ELISA method are 
faster than the mouse bioassay method, sensitive 
with high specificity, easy to standardize, and is 
commonly performed even to the level of public 
health  laboratories  (Sotelo  et  al.,  2011). In  the 
present  study  it  was  attempted  to  develop  an 
ELISA method to the C. botulinum toxin using the 
antibody which was developed locally. The results 
should  provide  a  better  understanding  of  the 
development of the method as well as to carry out 
an early  protection  against  the spreading  of  C. 
botulinum in the farm and animal industries.
MATERIALS AND METHODS
Polyclonal Antibody Production
Polyclonal antibodies used in this study were 
generating  locally  by  Depamede  and  Kisworo 
(2009).  Polyclonal  antibodies  were produced  in 
mice based on Dixit  et al.,  (2006) and Keller  et  
al., (2008) with some modifications as mentioned 
by  Depamede  and Kisworo  (2009).  Six  female 
Balb/c  mice  aged  6-8  weeks  were  immunized 
with  a  commercial  type B  C.  botulinum toxoid 
(Lot No. B121908-01, Metabiologics,  Inc., U.S). 
Mice were immunized 3 times for 8 weeks with a 
dose of 100 ng per mouse with 4 weeks interval. 
In  the  initial  immunization,  toxoid  was  mixed 
with complete Freund's adjuvant (CFA, Sigma) to 
form an emulsion. On the second immunization a 
mixture with incomplete Freund's adjuvant (ICFA, 
Sigma) was performed.  The first  and the second 
injection were carried out subcutaneously,  while 
the third injection (at  week 8) was administered 
intramuscularly.  As  a  control,  Balb/c  mice were 
injected concurrently with the treatments but the 
toxoid  was  replaced  with  physiological  saline 
solution.  Fourteen days after final immunization, 
serum of  each treatment  group and control  was 
taken from the mouse tail.  The serum was  then 
frozen at -20°C until processed for purification. 
Isolation  and  Purification  of  Polyclonal 
Antibodies
Isolation  and  purification  of  polyclonal 
antibodies against BoNTs-B toxin generated from 
Balb/c  mice  was  carried  out  by  50%  (w/v) 
ammonium  sulfate  precipitation  and  Protein  A 
column methods (Baumgarten, 1992). The purity 
of  the  antibody  was  analyzed  using  sodium 
dodecyl  sulfate  polyacrylamide  gel 
electrophoresis  (SDS-PAGE)  according  to 
Hempelmann (1992).
Development of ELISA 
The  isolated  antibodies  and  a  commercial 
antibody (Abcam) were used to develop sandwich 
ELISA according to Farzamfar  et al. (2007) with 
slight  modification  as  performed  by  Depamede 
and Kisworo  (2009).  ELISA plates  were  firstly 
coated  with  rabbit  anti  type  B  (RaCB)  C. 
botulinum toxin commercial (Abcam) as the first 
antibody layer. Each well was coated with 100 µL 
(2  µg/ml)  antibody in carbonate  buffer  solution 
pH 9.5 and then allowed to stand at 4°C for 12 
hours.  After  that  the  solution  was  discarded, 
replaced  with  300  µL  blocking  solution  (PBS 
containing  0.05% (v/v)  Tween 20  (Sigma),  and 
0.5% (w/v) bovine serum albumin) and allowed to 
stand for  60  minutes  at  room temperature.  The 
plates  were  then  washed  five  times  with  300 
µL/well  of  washing  solution  (PBS  containing 
0.05% (v/v) Tween 20). After washing, the wells 
were  filled  with  50  µL/well  of  standard 
commercial  ELISA  for  C.  botulinum toxin 
(Metabiologics, Inc.) with a concentration of 100 
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ng,  1  ng,  0,2  ng,  0.1  ng,  and  0  ng/ml,  and 
incubated for 60 min at room temperature. Then 
the plate was washed again 5 times and then 50 
µL of polyclonal antibody generated in this study 
as the second layer, concurrently with the controls 
was added in to the wells  and incubated for  60 
minutes  at  room  temperature.  The  purpose  of 
these  second  layer  antibodies  are  as  a  linker 
between  suspected  antigen  (BoNTs)  in  the 
samples  and  the  enzyme  Horseradish 
peroxidase(HRP)-conjugated  antibody.  After 
washing,  50  µL  goat-anti-mouse  IgG  HRP-
conjugated  antibodies  were  dropped  into  the 
ELISA  plate  wells  and  incubated  again  for 
another 60 minutes at room temperature. After the 
last  wash,  a  50  µL substrate  was  added  to  the 
wells and incubated for 5-10 minutes in the dark, 
at  room  temperature  until  the  reaction  color 
changes  in  the  positive  samples  occurred.  The 
reaction  was  stopped  by  adding  50  µL of  1  N 
H2SO4 then the reaction products were quantified 
by ELISA photo reader  (DYNEX-MRX) on the 
optical density of 450 nm (OD 450). 
Data Analysis 
The  data  obtained  were  tabulated  and 
analyzed by a  simple arithmetic  mean (Mean ± 
SD)  of  the  OD 450  (Drouet  et  al.,  2003)  and 
presented as reported by Depamede and Kisworo 
(2009).  The  calculation  of  the  limit  value  of 
positive  or  negative  test  results  (cut-off  value, 
COV) is calculated based on Drouet et al.  (2003), 
ie, COV = average value of negative controls ± 3 
x SD of  negative control value.  Samples with a 
COV ≤ OD 450 value was designated negative, 
while  a  greater  than  COV  was  positive 
(Depamede and Kisworo, 2009).
RESULTS AND DISCUSSION
Of the six Balb/c mice used, one animal died 
during  the  study  due  to  unknown  reasons,  but 
certainly not as a result of vaccination. Of the 5 
mice  leaved,  4  (80%)  gave  a  positive  immune 
response  or  produced  polyclonal  antibodies 
against  type B  C.  botulinum toxin,  and  one  of 
them gave a quite high immune response,  while 
one was with the lowest immune response (+/-) as 
presented in Table 1.
From  these  results  it  appears  that  the 
immune response of Balb/c mice was individually 
quite  disperse  (variation  value  was  about 
47.63%), and only one mouse gave high enough 
immune response.  These results were consistent 
with previous studies, especially when the vaccine 
or  immunogen  used  was  a  commercial 
immunogen;  native  immunogen  reported  to  be 
more immunogenic than those of the commercial 
toxoid (Witcome et al., 1999; Keller, 2008). In the 
present study, immunogen used was a commercial 
C.  botulinum toxoid.  Technically,  the  use  of 
commercial immunogen is more secure than the 
intact  or  native immunogen derived  or  isolated 
directly from C. botulinum. 
Furthermore, from the results of this study as 
reported also by Depamede and Kisworo (2009), 
it was noted also that the dose of 100 ng/ml gave 
a  significant  immune  response  (p<0.05)  on  the 
production  of  polyclonal  antibodies  (Figure  1). 
Polyclonal antibodies obtained were then purified 
by  ammonium sulfate  precipitation  method  and 
the  protein  A  'home  made  mini-column'.  The 
results of purification were analyzed using SDS-
PAGE as shown in Figure 1. From this figure, it 
clear  knwn that the antibody obtained was quite 
pure. 
Polyclonal antibody obtained was then used 
as  a  component  of  the  development  of  indirect 
ELISA as mentioned in the mateials and methods 
or  as  explained  elsewhere  by  Depamede  and 
Kisworo  (2009).  Preliminary  results  of  the 
developed ELISA method in  this  study showed 
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Table 1.  Immune Response of Balb/c mice Against C. botulinum Toxoid
Balb/c Code
The mean value
OD450 (n=3)
Immune Response
(COV=0.350)
1 0.580 +
2 1.156 +++
3 †) †)
4 0.423 +/-
5 0.500 +
6 0.642 +
†) Mouse died during the study
(Source: Depamede and Kisworo, 2009).
that polyclonal antibodies generated in this study 
can be used as a component of ingredients needed 
to develop  immunoassay such as ELISA against 
C. botulinum toxin.  Figure  2  shows  that  the 
developed ELISA was  able  to detect  type B  C. 
botulinum toxin  up  to  a  concentration  of  1.0 
ng/ml.
When compared to  the  in  vivo  mouse bio-
assay  test,  the  results  of  this  preliminary  study 
were  yet  as  sensitive  as  the  bio-assay  method. 
Bio-assay method was able to detect the toxin of 
C. botulinum from 0.01 up to 0.02 ng (Witcome et 
al., 1999). Although the bio-assay method is more 
sensitive,  as  mentioned  elsewhere,  the  method 
requires  animals  with  special  handling,  special 
skills, and time consume. Furthermore, there is a 
consideration  of  restrictions  on  the  use  of  trial 
animals  that  increasingly  constricted  in  the  last 
few  decades  (Witcome  et  al.,  1999).  These 
considerations have led the researchers to develop 
a more practical method of testing by applying the 
principles of immunodiagnostics such as ELISA. 
Lee  et al.  (2005), Atassi (2006), and Keller 
(2008) suggested that if immunodiagnostics need 
to  be  developed, it  would  be  better  if  using 
antibodies produced from modified C.  botulinum-
intact  toxin.  They  found  that  "home-made 
vaccine" from native C. botulinum antigens were 
more  immunogenic  and  more  protective  than 
those  of  commercial  antigens  (Keller,  2008). 
Furthermore,  Witcome et  al.  (1999) has 
successfully  developed a  modified  ELISA test 
using monoclonal antibodies produced from the 
modified native C.  botulinum antigens. It  was 
claimed  that  the  modified  ELISA was  able  to 
detect the C. botulinum toxin up to 0.005 ng, or in 
other  words  two  times  more sensitive  than  the 
bio-assay method, which was able to detect  0.01 
ng (Witcome  et al., 1999).  From this account,  it 
can  be  revealed  here  that  the  quality  of  the 
antibodies obtained in this preliminary study to be 
used as component for the development of ELISA 
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Figure 1.  Effects of a Commercial C.  botulinum Toxoid Vaccine Dosages on Production of Polyclonal 
Antibodies of Local Balb/c Mice (a) and a Representative Result  of 12.5% SDS-PAGE Analysis of 
Polyclonal Antibodies (arrow) Purified by Protein A Column (b). 
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can still be improved further. 
CONCLUSIONS 
An  ELISA kit  for  detecting  C.  botulinum 
toxins has been developed by applying polyclonal 
antibodies against  C. botulinum generated locally 
in this preliminary study. 
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